Jean-Jacques Kiladjian: The new findings of Proud-Continuation PV randomized trial

Jean-Jacques Kiladjian, Professor of Clinical Pharmacology at Paris Diderot University, shared a post on X:

“Don’t miss the new findings of Proud-Continuation PV randomized trial showing the correlation between JAK2 mutation reduction with ropeginterferon alpha 2b and better event-free survival!

Molecular response is a meaningful goal of therapy in PV.”

Source: Jean-Jacques Kiladjian/X